Therapeutic Drug Monitoring for Subcutaneous Infliximab? Too Early to Conclude
- PMID: 36610500
- DOI: 10.1016/j.cgh.2022.12.028
Therapeutic Drug Monitoring for Subcutaneous Infliximab? Too Early to Conclude
Comment on
-
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.Clin Gastroenterol Hepatol. 2023 Aug;21(9):2338-2346.e3. doi: 10.1016/j.cgh.2022.08.011. Epub 2022 Aug 17. Clin Gastroenterol Hepatol. 2023. PMID: 35987302
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources